Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction

Current Opinion in Cardiology

Volumn 13, Issue 4, 1998, Pages 274-279

  Bates, Eric R ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HEPARIN; LAMIFIBAN; STREPTOKINASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGIOPLASTY; CLINICAL TRIAL; CORONARY ARTERY DILATATION; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; STENT;

EID: 0031822485     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199807000-00008     Document Type: Review

References (21)

1. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993, 329:1615-1622.
2. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997, 336:1621-1628.
3. Topol EJ: Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998, 97:211-218. This review article summarizes the current perspectives and future directions for antiplatelet therapy in acute myocardial infarction.
4. Granger CB, White HD, Bates ER, Ohman EM, Califf RM: A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 1994, 74:1220-1228.
5. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC: Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation 1997, 95:1755-1759. This is the first report describing the use of platelet receptor antagonists as thrombolytic agents.
6. Gold HK, Kereiakes DJ, Dinsmore RE, Martin LH, Lausten D, Broderick TM, Anderson KM, Garabedian HD, Leinbach RC: A randomized, placebo-controlled crossover trial of ReoPro alone or combined with low-dose plasminogen activator for coronary reperfusion in patients with acute myocardial infarction: preliminary results [abstract]. Circulation 1997, 96:1-474.
7. Merkhof-Van Den LFM, Liem A, Zijlstra F, Olsson H, Nilsson H, Grip L, Veen G, de Zwaan C, Bar FW, van der Zwaan C, Simoons ML, Verheugt FWA: early coronary patency evaluation of a platelet glycoprotein receptor antagonist (abciximab) in primary PTCA: the GRAPE pilot study [abstract]. Circulation 1997, 96:1-474.
8. th International Workshop: Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, Orlando, FL, November 1997.
9. th International Workshop: Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, Orlando, FL, November 1997.
10. Makkar R, Eigler N, Goff B, Fry E, Barr L, D'Haem C, Fischell T, Litvack F: Primary reperfusion in acute myocardial infarction with ReoPro and heparin: interim results of ReoMI pilot study [abstract]. J Am Coll Cardiol 1998, 31:191A.
11. Glatt B, Guyon P, Chevalier B, Royer T, Jullien T, Hennequin B, Herlin C, Sebbah JL, Belotte F, Dambrin G: Pre-hospital treatment with abciximab in acute myocardial infarction with direct percutaneous transluminal coronary angioplasty [abstract]. J Am Coll Cardiol 1998, 31:230A.
12. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993, 22:381-389.
13. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley D, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ: Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997, 95:846-854.
14. Ronner E, van Kesteren HAM, Zijnen P, Tebbe, Molhoek P, Cuffie C, Veltri E, Lorenz T, Neuhaus K, Simoons ML: Combined therapy with streptokinase and integrilin [abstract]. J Am Coll Cardiol 1998, 31:191A.
15. The PARADIGM Investigators: Enhancement of thrombolysis with concomitant use of the platelet glycoprotein IIb/IIIa inhibitor lamifiban: the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. Circulation, in press.
16. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ: Effects of platelet Glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996, 77:1045-1051.
17. Brener SJ, Barr LA, Burchenal J, Katz S, George BS, Jones AA, Moliterro DJ, Topol EJ: A randomized placebo-controlled trial of abciximab with primary angioplasty for acute MI: the RAPPORT trial [abstract]. Circulation 1997, 96:1-473.
18. Miller JM, Ohman EM, Schildcrout JS, Smalling RW, Betnu A, Califf RM Topol EJ: Survival benefit of abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III Trial [abstract]. J Am Coll Cardiol 1998, 31:94A.
19. Sundlof DW, Reprkpattanapitat P, Wongpraparut N, Pathl P, Kotler MN, Jacobs LE, Yazdanfar S: Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring angioplasty [abstract]. J Am Coll Cardiol 1998, 31:238A.
20. th International Workshop: Thrombolysis and Intervention Therapy in Acute Myocardial Infarction, Orlando, FL, November 1997.
21. Stone GW: Stenting and IIb/IIIa receptor blockade in acute myocardial infarction: an introduction to the CADILLAC trial. J Invas Cardiol 1998, 10:36B-47B.